Starpharma today announced that AstraZeneca has selected a second DEP™ candidate and Starpharma will now commence a new DEP™ project incorporating the second proprietary AstraZeneca oncology molecule.

Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 2.00pm today.

Download: AGM - Chair address and CEO presentation (pdf file, 1MB)

The Australian's Sarah-Jane Tasker reports that "Starpharma's shares have hit a fresh high following positive results in a preclinical trail for its ovarian cancer model. The company said a cancer drug treatment coupled with its dendrimer (DEP) technology - which allows for more effective drug delivery - had resulted in complete tumour regression and 100 per cent survival in a preclinical trial done on mice."

Go to the artice (external link)

Melbourne, Australia; Starpharma today announced that treatment with its novel antibody-targeted DEP^® conjugate resulted in complete tumour regression and 100% survival in an ovarian cancer model.

Starpharma today announced it has received the anticipated $3.4M of R&D tax incentive refund related to FY15 expenditures.

Starpharma today announced that it will present at the Bio-Europe^® conference in Munich which is being held this week. At the conference Starpharma will also be conducting partnering discussions for VivaGel^® BV and DEP™ with pharmaceutical companies.

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 September 2015.

In this Issue:

› EU marketing approval granted for VivaGel^® BV
› Multi-product DEP^® license with AstraZeneca
› VivaGel^® BV: Symptomatic Relief and Treatment of BV/Prevention of recurrence
› VivaGel^® condom
› Phase 1 DEP® docetaxel trial update                                                                                    

› Agrochemicals
› Starpharma in the News
› Starpharma full year financial results      

› Presentations and conferences

Download: Shareholder Update October 2015 (pdf file, 994kb)

Starpharma today announced the granting of a patent by the US Patent Office for VivaGel^® related to the prevention of recurrence of bacterial vaginosis (BV). The patent’s term is to 2032 providing an extension of seven years over granted VivaGel^® patents. Additional term may also be available subject to timing of regulatory approval.

Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that as part of its OTCQX  investor communications, a pre-recorded presentation by Chief Executive Officer Dr Jackie Fairley will be broadcast at VirtualInvestorConferences.com on Thursday, October 1, 2015 at 12.15pm (EDT time). The presentation is part of a special OTCQX Life Sciences virtual Conference.